Baviera, Marta
Foresta, Andreana
Colacioppo, Pierluca
Macaluso, Giulia
Roncaglioni, Maria Carla
Tettamanti, Mauro
Fortino, Ida
Genovese, Stefano
Caruso, Irene
Giorgino, Francesco
Funding for this research was provided by:
Regione Lombardia (DGR n. 3375 del 14-07-2020)
Article History
Received: 30 May 2022
Accepted: 10 July 2022
First Online: 24 August 2022
Declarations
:
: Not applicable.
: Not applicable.
: Marta Baviera, Andreana Foresta, Pierluca Colacioppo, Giulia Macaluso, Maria Carla Roncaglioni, Mauro Tettamanti, Ida Fortino, Irene Caruso declare no conflict of interest. Francesco Giorgino receives research support from Eli Lilly, Lifescan, and Roche Diabetes Care; is a consultant for Boehringer Ingelheim, Lifescan, Merck Sharp & Dohme, Sanofi, AstraZeneca, and Roche Diabetes Care; and is on the advisory boards for AstraZeneca, Eli Lilly, Novo Nordisk, Roche Diabetes Care, and Sanofi. Stefano Genovese received research funding from Novartis and has been a consultant for, or received honoraria from Abbott Diabetes Care, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hikma Pharmaceuticals, Janssen, Menarini, Merck Sharp & Dohme, Molteni Farmaceutici, Mundipharma, Novartis, Novo Nordisk, Sanofi, Takeda, Teva and Zentiva.